Vertex (VERX) announced the latest enhancement of Vertex e-Invoicing – a comprehensive solution designed to simplify electronic invoicing for businesses navigating increasingly complex global ...

Stifel Nicolaus analyst Brad Reback maintained a Hold rating on Vertex (VERX – Research Report) today and set a price target of $31.00. The company’s shares closed yesterday at $36.45.

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is ...

KING OF PRUSSIA, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced ...

In the latest quarter, 8 analysts provided ratings for Vertex VERX, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts ...

With a powerful logo and striking color, the brand captures and amplifies the spirit and energy of the WTA, bringing the drama of women's tennis to life like never before. Honoring the WTA's ...

The best logo maker is an essential design tool for anyone looking to differentiate their brand online. My round-up here offers apps ideal for designers and non-designers who need to help their ...

The best free logo maker is a great choice for those who need to create logos for their businesses without paying for subscriptions or licenses. I'll cut to the chase: for a free logo designer ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer discusses. In a recent appearance on CNBC’s ...